Delineating the pathogenesis of multifactorial diseases is a major challenge of the postgenomial era. Genetic factors are known to play an important role in the pathogenesis of certain psychiatric disorders as well as in the development of adverse reactions to psychoactive drugs. Containing large numbers of samples and linking them clinical data, biobanks are gaining importance in the studies of chronic multifactorial diseases. Several biobanks are under establishment in Hungary. The first initiative to collect samples in neurological and psychiatric disorders was the NEPSYBANK coordinated by the Hungarian Society of Clinical Neurogenetics. The national biobank network is currently established by the NEKIFUT project of the National Office of Research and Technology. In this article we describe the structure, logistics and informatical background of the national schizophrenia biobank (SCHIZOBANK). The initiative of the SCHIZOBANK originates from a consortium in which academy and health industry partners are collecting biological materials and data in five major psychiatric center under the coordination of the Medical and Health Science Center of the University of Debrecen. We review other international schizophrenia biobanks as well. Major strength of the SCHIZOBANK is the collection of very detailed phenotypic data and of RNA and plasma both in psychotic and non-psychotic state of the patient which permits longitudinal follow-up and the study of both static and dynamically changing transcriptomic, proteomic and metabolomic markers. The collection of the SCHIZOBANK is available not only to consortial partners but to other national and international research groups as well.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1556/OH.2010.28943 | DOI Listing |
Int J Soc Psychiatry
January 2025
Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Patients with serious mental illness (SMI) often engage in religious and superstitious activities. The implications of such engagements remain unclear, with no established guidelines for mental health professionals.
Aims: This study aimed to survey perspectives and gather suggestions from various disciplines within mental healthcare regarding the engagement in religious/superstitious activities of SMI patients: schizophrenia spectrum disorders, bipolar disorder, major depressive disorder.
Molecules
January 2025
School of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng 252059, China.
Dopamine (DA) is an important catecholamine neurotransmitter and its abnormal concentration is closely related to diseases such as hypertension, Parkinson's disease and schizophrenia. Due to the advantages of high sensitivity and fast response for electrochemiluminescence (ECL), developing ECL sensors for detecting DA was very critical in clinical diagnosis. ECL resonance energy transfer (ECL-RET) was an effective signaling mechanism.
View Article and Find Full Text PDFJ Comp Neurol
January 2025
Graduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, USA.
Glutamate delta receptor 1 (GluD1) is a unique synaptogenic molecule expressed at excitatory and inhibitory synapses. The lateral habenula (LHb), a subcortical structure that regulates negative reward prediction error and major monoaminergic systems, is enriched in GluD1. LHb dysfunction has been implicated in psychiatric disorders such as depression and schizophrenia, both of which are associated with GRID1, the gene that encodes GluD1.
View Article and Find Full Text PDFPharmaceut Med
January 2025
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
Background And Objectives: Drug development in schizophrenia is limited by the differential scaling of the active treatment and placebo arms of a study, such that, as the number of sites increases, the magnitude of placebo response disproportionately increases. The objective of this article was to identify factors conducive to efficient recruitment as a step towards trial designs allowing recruitment of more participants per site, leading to reduced variability, and potentially a smaller placebo effect.
Patients And Methods: Using the information of 554 individuals, we calculated the percentage of individuals who were screened, consented, and retained in our research, along with rationale for nonconsent.
J Neuropsychiatry Clin Neurosci
January 2025
Department of Psychology, Chung Shan Medical University, and Clinical Psychological Room, Chung Shan Medical University Hospital, Taichung, Taiwan (Huang); Department of Psychology, Fo Guang University, Yilan, Taiwan (Chen); Come a New Halfway House, Taoyuan, Taiwan (Wang); Department of Psychiatry, National Cheng Kung University Hospital (Kuo, Yang, Tseng), and Institute of Behavioral Medicine (Yang, Tseng), College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Objective: Social cognition is defined as the ability to construct mental representations about oneself, others, and one's relationships with others to guide social behaviors, including referring to mental states (cognitive factor) and understanding emotional states (affective factor). Difficulties in social cognition may be symptoms of schizophrenia. The authors examined associations between two factors of social cognition and specific schizophrenia symptoms, as well as a potential path from low-level affective perceptual social cognition to high-level social cognition, which may be associated with schizophrenia symptoms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!